Yun S Kang

US Patent:

6365147, Apr 2, 2002

Filed:

Oct 13, 1999

Appl. No.:

09/416934

Inventors:

Robert Gang Luo - Edison NJ
Yun Kang - Harrison NJ

Assignee:

New Jersey Institute of Technology - Newark NJ

International Classification:

A01N 6300

US Classification:

424 931, 604 502, 210661, 210670, 210691, 210692

Abstract:

The present invention relates to methods for depleting endotoxin from biological solutions by exposure of solutions containing endotoxin to an immobilized metal affinity chromatography matrix composed of a metal ion such as iron (III) bounds to a resin, wherein the metal is capable of selectively binding endotoxin in the solution. These methods are useful for purifying, for example, biological products prepared using bacterial cells, or products in which bacterial contamination is problematic. In another embodiment, endotoxin in circulation in a body can be removed by exposing the blood to the aforementioned matrix, whereby endotoxin is removed before the blood is returned to the body.

US Patent:

7875446, Jan 25, 2011

Filed:

Apr 19, 2007

Appl. No.:

11/788071

Inventors:

Yun Kang - Livingston NJ, US
Mark William Cutler - Bloomingdale NJ, US
Amadou Affrey Ouattara - New Milford NJ, US
Kristen Elissa Syvertsen - Tarrytown NY, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

C12N 7/02
C12N 1/02
C12N 7/01
A61K 39/205
A61K 39/38
A61K 39/12
A01N 63/00
A61K 39/23

US Classification:

435239, 4242241, 4241841, 4242041, 424 936, 424 931, 435261, 4352351

Abstract:

A process is described for purifying vesicular stomatitis virus (VSV) from cell culture fluid of a mammalian cell culture infected with VSV, the process comprising: clarifying the cell culture fluid by low-speed centrifugation and recovering the VSV in the supernatant; filtering the supernatant through a 0. 2 to 0. 45 μm filter and recovering the VSV in the filtered solution; loading the VSV filtered solution onto a anion exchange membrane adsorber equilibrated with a first pH buffered salt solution, eluting the VSV from the anion exchange membrane adsorber with a second pH buffered salt solution and recovering the eluted VSV fractions; purifying the recovered VSV by tangential flow filtration (TFF) using a TFF membrane having a molecular weight cutoff between 300 kDa and 1,000 kDa and recovering the VSV in the retentate, and filtering the VSV retentate through a 0. 2 to 0. 22 μm filter and recovering the VSV in the filtered solution.

US Patent:

7939083, May 10, 2011

Filed:

Oct 17, 2007

Appl. No.:

12/312016

Inventors:

Antu K. Dey - Auburndale MA, US
John P. Moore - New York NY, US
William C. Olson - Yorktown Heights NY, US
Yun (Kenneth) Kang - Livingston NJ, US
Michael Franti - Cambridge MA, US

Assignee:

Progenics Pharmaceuticals Inc. - Tarrytown NY

International Classification:

A61K 39/21
A61K 39/12

US Classification:

4242081, 4241881, 4241991

Abstract:

This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof. Also provided are antibodies generated against the modified polypeptides and trimeric complexes, and methods of using the modified polypeptides, compositions and trimeric complexes.

US Patent:

20060246544, Nov 2, 2006

Filed:

Mar 30, 2006

Appl. No.:

11/396215

Inventors:

Yun Kang - Livingston NJ, US
Walter Willett - Doylestown PA, US
Thomas Klimek - Philadelphia PA, US
Basil Campbell - Gaithersburg MD, US
Paul Cino - Jamison PA, US
Bradley Thomas - Quakertown PA, US
John Bermel - Telford PA, US
Chun-Chiang Chen - Gaithersburg MD, US

Assignee:

Neose Technologies,Inc. - Horsham PA

International Classification:

C12P 21/06
C12N 9/24
C12N 5/06
C07K 14/53
C07K 14/51

US Classification:

435069100, 435320100, 435348000, 435200000, 530351000, 530414000, 530399000

Abstract:

The present invention provides a manufacturing method for the production of peptides that are grown in insect cell lines. The peptides are grown in insect cell cultures that are infected with baculovirus particles in a culture supplemented with a lipid mixture. The peptides are then isolated from the insect cell culture using a method that employs a tangential flow filtration cascade. The isolated peptides are glycopeptides having an insect specific glycosylation pattern. The glycopeptides may then be conjugated to a modifying group via linkage through a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase.

US Patent:

20110250220, Oct 13, 2011

Filed:

May 4, 2011

Appl. No.:

13/100941

Inventors:

Antu K. Dey - Auburndale MA, US
John P. Moore - New York NY, US
William C. Olson - Yorktown Heights NY, US
Yun (Kenneth) Kang - Livingston NJ, US
Michael Franti - Cambridge MA, US

International Classification:

A61K 39/21
A61P 31/18
A61P 37/04
C07K 14/16
C12P 21/00

US Classification:

4241881, 530350, 435 693

Abstract:

This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof. Also provided are antibodies generated against the modified polypeptides and trimeric complexes, and methods of using the modified polypeptides, compositions and trimeric complexes.